Le Lézard
Classified in: Health, Science and technology
Subject: Funding

Dyne Therapeutics Announces $115 Million Financing to Advance Pipeline of Modern Oligonucleotide Therapeutics for Serious Muscle Diseases


Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapies for patients with serious muscle diseases, today announced the closing of a $115 million equity financing led by new investors Vida Ventures and Surveyor Capital (a Citadel company). Additional new investors, including Wellington Management Company, Logos Capital, Franklin Templeton and an undisclosed institutional investor were joined by existing investors Atlas Venture, Forbion and MPM Capital.

"We are excited to have such strong support from outstanding new and existing investors who share the Dyne team's vision of building the world's leading muscle disease company," said Joshua Brumm, president and chief executive officer of Dyne. "Importantly, this capital allows us to leverage our FORCEtm platform and advance our pipeline of modern oligonucleotide therapeutics aimed at transforming the lives of individuals living with serious muscle diseases."

The financing accelerates the development of Dyne's pipeline of muscle disease therapies, including its lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD), as well as additional indications, including cardiac and metabolic muscle diseases.

"Dyne's FORCE platform has the potential to deliver life-changing outcomes for patients with debilitating muscle diseases," said Stefan Vitorovic, co-founder and managing director of Vida Ventures. "We are excited to partner with Dyne and its stellar team as the Company advances its programs and pursues its bold vision."

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The Company utilizes its proprietary FORCEtm platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit www.dyne-tx.com, and follow us on Twitter, LinkedIn and Facebook.


These press releases may also interest you

at 15:20
Aventiv Technologies, a communications and technology business serving the incarcerated, their friends and family, and state and local correctional facilities, today announced an agreement...

at 15:15
Dentsu announced today the official launch of Merkury for Media, the network's latest offering within its unrivaled global data, identity, and insights platform, Merkury. The new...

at 15:11
The technology service provider market is at a crucial turning point, marked by exponential technological innovation,...

at 15:10
ServiceChannel, the leading platform for the procurement and delivery of facilities services, announced today the introduction of new solutions that empower business operators to maximize their facilities investments. The Spring 2024 Product...

at 15:05
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent directors Cristian Luput and Ramiro Guerrero, J.D, LL.M. made individual...

at 15:01
G FUEL and Gearbox Entertainment Company celebrate gaming icon Duke Nukem with Ego Boost, a new zero-sugar Energy Formula now available at GFUEL.com. Fans can purchase the cherry, orange, and pomegranate flavor as a 40-serving standalone powder Tub...



News published on and distributed by: